About Excell Research

Our Mission

Excell Research’s mission is to provide comprehensive clinical research services that expand the knowledge and application of new medication therapies for a variety of psychiatric and neurological disorders. 

We are dedicated to improving the lives of patients through the advancement of safe and effective medication therapies.

Our Values

At Excell Research, we are committed to:

Delivering timely and accurate data that fosters the drug development process

Providing patients and their families with a compassionate, supportive research environment

Upholding scientific and ethical integrity

Educating our team members in the latest medical advances

Perla 2022

Our Team

jelena-kunovac-md-excell-research2

Jelena Kunovac, M.D., M.S.

Dr. Jelena Kunovac serves as Co-Founder and Chief Executive Officer of Excell Research, as well as Founder and Chief Executive Officer of Altea Research in Las Vegas and Alea Research in Phoenix. She has over 25 years of experience in the clinical trials industry.
Dr. Kunovac conducts Phase I to Phase IV clinical trials, primarily in the CNS area. She serves on scientific and pharmaceutical Editorial and Advisory Boards. Prior to dedicating her career to clinical research, Dr. Kunovac was a practicing psychiatrist.

In addition, she is an Adjunct Assistant Professor of Psychiatry at the University of Nevada, Las Vegas. Dr. Kunovac regularly authors scientific publications in respected medical journals and presents her research at scientific meetings around the world.

Dr. Kunovac is Board Certified in Psychiatry. She completed Residency Training in Psychiatry at the University of California, San Diego (UCSD). While at UCSD, Dr. Kunovac was a NIMH fellow. Previously, she received a Master’s Degree in Biological Psychiatry and an M.D. from the University Of Belgrade School Of Medicine where she graduated as the Valedictorian of her class.

As a former TV talk show host in her native Yugoslavia, Dr Kunovac is in great demand as a public speaker, and travels all over the world teaching and lecturing doctors and other health care professionals on advances in the field.

Read More
sherry-soefje-md-excell-research

Sherry Soefje, M.D.

Dr. Sherry Soefje is Co-Founder, Chief Financial Officer and Medical Director of Excell Research. Bringing close to 30 years of clinical trials experience, Dr. Soefje has participated in over 250 clinical trials in the CNS area, and has been the Principal Investigator for Excell Research since 2012.
Dr. Soefje conducts Phase II to IV studies in the CNS area including schizophrenia, bipolar disorder, Alzheimer’s disease, depression, and anxiety disorders.

Over the past 30 years, Dr. Soefje has dedicated her time and efforts to people and families affected by mental illnesses through helping advance the development of new treatments.

Read More

Our Experience

Excell Research: Areas of Study

Central Nervous System Disorder Studies:
Alzheimer’s Disease
Attention Deficit Hyperactive Disorder
Bipolar Disorder
General Anxiety Disorder
Insomnia
Major Depressive Disorder
Mild Cognitive Impairment
Obsessive-Compulsive Disorder
Post-Traumatic Stress Disorder
Postpartum Depression
Schizophrenia

Women’s Health Studies:
Endometriosis
Hypoactive Sexual Desire Disorder
Polycystic Ovarian Syndrome
Uterine Fibroids

General Medical Health Studies:
Chronic Idiopathic Constipation
Essential Tremors
Fibromyalgia
Migraines
Opioid Induced Constipation
Tardive Dyskinesia

Excell Research may be seeking participants for an upcoming clinical research study for an area or disease that is relevant to you or someone you know.

Partner Pharmaceutical Companies and Researchers

Abbott
ACADIA
AgeneBio
Alder Biopharmaceuticals
Alkermes
Allergan
Amarex
Amgen
Aptinyx
Astellas
Avanir Pharmaceuticals
Axsome Therapeutics
Bionomics
Biohaven Pharmaceuticals
Biogen Pharmaceuticals
Braintree Laboratories,Inc.
CeNeRx
Cerecor
Chiltern
Clexio
Corcept
Daiichi Sankyo Pharma Development
DeNovo Biopharma
Edgemont Pharmaceuticals, Inc.
Eisai
EnVivo
Evidara
Evotec
Fanapt
Forest Pharmaceuticals
GATE
GW Research
Impel NeuroPharma
Janssen
JAZZ Pharmaceuticals, Inc.
Karuna Therapeutics
Lilly
Lundbeck
Marinus
MediVector
Merck Corporation
Millendo Therapeutics, Inc.
Methylation Sciences, Inc.
Myovant
Nektar
Neurocrine Biosciences
Novartis
Ogeda
Otsuka Pharmaceuticals
Palatin Technologies, Inc.
Pfizer
Pharmascience, Inc.
Praxis
Reckitt Benckiser Pharmaceuticals, Inc.
Relmada
Rexahn Pharmaceuticals
Roche
Sage
Schering-Plough
Sepracor
Shionogi
Swing Therapeutics
Sunovion
Takeda
Targacept
TauRx Therapeutics LTD
TEVA
Tonix
University of Arizona
University of Montana
Vanda
Virios
Vistagen
Wyeth